What is Arbutus Biopharma Corporation's earnings per share (EPS)?

Arbutus Biopharma Corporation (ABUS) reported diluted earnings per share of -$0.17 for fiscal year 2025. This represents a 55.3% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Arbutus Biopharma Corporation (ABUS) Financials

ABUS

FY2025 annual

Revenue $14.1M +128.2% YoY

Net Income -$33.5M +52.1% YoY

EPS (Diluted) -$0.17 +55.3% YoY

Free Cash Flow -$39.6M +39.1% YoY

Market Cap $836.0M as of Oct 17, 2026

Price / Sales 4.6x on $181.7M revenue, trailing 12 months to June 30, 2026

Price / Earnings 5.5x on $153.1M net income, trailing 12 months to June 30, 2026

Price / Book 3.2x on $258.7M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 17, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 12, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 12, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ABUS SEC filings page.

Arbutus Biopharma Corporation (ABUS) reported $14.1M in revenue for fiscal year 2025, up 128.2% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI ABUS FY2025 2026-10-04

Arbutus remains a development-stage business: lower spending reduced losses and cash use, while revenue is still too small to fund operations.

In FY2025, operating cash flow was -$39.6M against a net loss of $33.5M; the similar relationship in FY2024 indicates losses were largely cash-based rather than driven by large noncash charges. That pattern makes the improved result more a consequence of reduced spending than of revenue economics.

Revenue of $14.1M remained below R&D spending of $25.2M in FY2025, so reported sales did not yet finance core development spending. R&D's reduction helped improve cash use, making the year's better loss profile primarily spending-led.

At FY2025 year-end, the reported liquidity measure equaled 27.7 months of the latest annual operating outflow, and the current ratio was 15.7x; this describes substantial short-term coverage, not operating self-sufficiency. Total assets fell from $131.7M to $94.6M, showing that the balance sheet is shrinking even as immediate obligations remain comparatively light.

Financial Health Signals

Financial Health Score 63/100

Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Arbutus Biopharma Corporation's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway

Arbutus Biopharma Corporation held $91.5M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $39.6M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Arbutus Biopharma Corporation scores 53/100 among other emerging companies.

Dilution

Arbutus Biopharma Corporation had 195M shares outstanding at the end of fiscal year 2025, against 191M in fiscal year 2024. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Arbutus Biopharma Corporation scores 59/100 among other emerging companies.

R&D Intensity

Arbutus Biopharma Corporation spent $25.2M on research and development in fiscal year 2025, which was 48.3% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Arbutus Biopharma Corporation scores 77/100 among other emerging companies.

Revenue Progress

Arbutus Biopharma Corporation reported revenue of $14.1M in fiscal year 2025, against $6.2M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and Arbutus Biopharma Corporation scores 28/100 among other emerging companies.

Burn Trend

Arbutus Biopharma Corporation's operations used $39.6M of cash in fiscal year 2025, against $64.8M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and Arbutus Biopharma Corporation scores 73/100 among other emerging companies.

Balance Sheet

Arbutus Biopharma Corporation's cash, cash equivalents and investments came to $91.5M at the end of fiscal year 2025, against $18.0M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Arbutus Biopharma Corporation scores 89/100 among other emerging companies.

Altman Z-Score Safe

7.32

Arbutus Biopharma Corporation scores 7.32, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($836.0M) relative to total liabilities ($18.0M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

3/8

Arbutus Biopharma Corporation passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality No Cash Backing

N/A

Arbutus Biopharma Corporation reported a net loss of $33.5M while operations used $39.6M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

Arbutus Biopharma Corporation reported an operating loss of $38.2M against $97K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$1.0M

YoY-90.6%

QoQ-99.4%

5Y CAGR-15.3%

Arbutus Biopharma Corporation generated $1.0M in revenue in Q2 2026. This represents a decrease of 90.6% from the same quarter a year earlier. Against the prior quarter it is down 99.4%.

EBITDA

-$6.0M

YoY-497.1%

QoQ-103.5%

Arbutus Biopharma Corporation's EBITDA was -$6.0M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 497.1% from the same quarter a year earlier. Against the prior quarter it is down 103.5%.

Net Income

-$5.1M

YoY-303.8%

QoQ-103.0%

Arbutus Biopharma Corporation reported -$5.1M in net income in Q2 2026. This represents a decrease of 303.8% from the same quarter a year earlier. Against the prior quarter it is down 103.0%.

EPS (Diluted)

-$0.03

YoY-400.0%

QoQ-103.4%

Arbutus Biopharma Corporation earned -$0.03 per diluted share (EPS) in Q2 2026. This represents a decrease of 400.0% from the same quarter a year earlier. Against the prior quarter it is down 103.4%.

Cash & Balance Sheet

Cash & Debt

$19.2M

YoY-48.8%

QoQ-19.1%

5Y CAGR-9.1%

10Y CAGR-7.8%

Arbutus Biopharma Corporation held $19.2M in cash against $0 in long-term debt as of Q2 2026.

Shares Outstanding

198M

YoY+3.2%

QoQ+0.2%

5Y CAGR+14.8%

10Y CAGR+13.7%

Arbutus Biopharma Corporation had 198M shares outstanding in Q2 2026. This represents an increase of 3.2% from the same quarter a year earlier. Against the prior quarter it is up 0.2%.

Free Cash Flow

Not reported for Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Return on Equity

-2.0%

YoY-5.0pp

QoQ-67.2pp

5Y change+17.2pp

10Y change+28.1pp

Arbutus Biopharma Corporation's ROE was -2.0% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 5.0 percentage points from the same quarter a year earlier. Against the prior quarter it is down 67.2 percentage points.

Gross Margin

Not reported for Q2 2026.

Operating Margin

Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin

Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Capital Allocation

R&D Spending

$2.9M

YoY-47.3%

QoQ-29.7%

5Y CAGR-28.8%

Arbutus Biopharma Corporation invested $2.9M in research and development in Q2 2026. This represents a decrease of 47.3% from the same quarter a year earlier. Against the prior quarter it is down 29.7%.

Share Buybacks

Not reported for Q2 2026.

Capital Expenditures

Not reported for Q2 2026.

ABUS Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ABUS quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$181.7M	$14.1M+128.2%	$6.2M-66.0%	$18.1M-53.5%	$39.0M+255.1%	$11.0M+58.9%	$6.9M+15.0%	$6.0M+1.1%	$5.9M-44.4%	$10.7M+617.6%	$1.5M-93.6%	$23.3M+55.7%	$15.0M-3.3%	$15.5M+9.6%	$14.1M-16.1%	$16.8M
R&D Expenses	$17.8M	$25.2M-53.3%	$54.0M-26.7%	$73.7M-12.7%	$84.4M+28.9%	$65.5M+32.8%	$49.3M-14.3%	$57.6M-0.6%	$57.9M-7.6%	$62.7M+2.3%	$61.3M+18.9%	$51.5M+33.0%	$38.7M+80.4%	$21.5M+18.9%	$18.0M-10.4%	$20.1M
SG&A Expenses	$16.5M	$15.9M-28.1%	$22.1M-1.6%	$22.5M+26.0%	$17.8M+4.1%	$17.1M+15.4%	$14.8M-16.3%	$17.7M+10.8%	$16.0M-0.8%	$16.1M-59.1%	$39.4M+49.2%	$26.4M+204.5%	$8.7M+56.6%	$5.5M-31.9%	$8.1M+27.5%	$6.4M
Operating Income	$149.0M	-$38.2M+50.0%	-$76.3M+2.3%	-$78.1M-19.3%	-$65.5M+11.0%	-$73.5M-27.2%	-$57.8M+59.8%	-$143.9M-60.3%	-$89.8M+19.1%	-$110.9M+77.4%	-$491.6M-373.1%	-$103.9M-210.8%	-$33.4M-175.1%	-$12.2M+6.1%	-$12.9M-21.1%	-$10.7M
EBITDA	N/A	-$37.8M+49.6%	-$74.9M+2.3%	-$76.7M-19.8%	-$64.0M+10.8%	-$71.8M-28.6%	-$55.8M+60.6%	-$141.9M-62.0%	-$87.6M+19.6%	-$108.9M+77.8%	-$490.5M-374.7%	-$103.3M-214.0%	-$32.9M-185.2%	-$11.5M+4.5%	-$12.1M-24.4%	-$9.7M
Interest Expense	$76K	$97K-29.2%	$137K-70.2%	$459K-73.4%	$1.7M-39.6%	$2.9M-28.8%	$4.0M+90.3%	$2.1M+832.7%	$226K-13.4%	$261K	$0	$0	N/A	N/A	N/A	N/A
Income Tax	N/A	$0	$0	$0-100.0%	$4.4M	$0	$0+100.0%	-$12.7M-195.6%	-$4.3M+82.4%	-$24.3M+76.8%	-$105.0M-548.8%	-$16.2M	$0	$0	N/A	N/A
Net Income	$153.1M	-$33.5M+52.1%	-$69.9M+4.0%	-$72.8M-4.9%	-$69.5M+8.9%	-$76.2M-19.6%	-$63.7M+58.5%	-$153.7M-169.4%	-$57.1M+32.4%	-$84.4M+78.0%	-$384.2M-512.5%	-$62.7M-61.5%	-$38.8M-176.2%	-$14.1M-147.5%	$29.6M+393.7%	-$10.1M
EPS (Basic)	N/A	-$0.17+55.3%	-$0.38+13.6%	-$0.44+4.3%	-$0.46+44.6%	-$0.83+17.0%	-$1.00	N/A	-$1.21+22.4%	-$1.56+78.5%	-$7.24-424.6%	-$1.38+23.3%	-$1.80-95.7%	-$0.92-142.6%	$2.16+342.7%	-$0.89
EPS (Diluted)	$0.79	-$0.17+55.3%	-$0.38+13.6%	-$0.44+4.3%	-$0.46	-$0.83+17.0%	-$1.00	N/A	-$1.21+22.4%	-$1.56+78.5%	-$7.24-424.6%	-$1.38	-$1.80	-$0.92-144.4%	$2.07+332.6%	-$0.89
Diluted Shares (Avg)	N/A	192M+3.2%	186M+11.8%	166M+10.0%	151M	106M+40.1%	76M	N/A	55M+1.1%	55M+3.1%	53M+16.7%	45M	22M	15M+6.9%	14M+26.5%	11M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$1.0M-90.6%	$179.1M+10054.5%	$1.1M-33.2%	$529K-60.5%	$10.7M+522.2%	$1.8M+15.1%	$1.6M-26.6%	$1.3M-71.3%
R&D Expenses	$2.9M-47.3%	$4.1M-54.0%	$5.0M-43.2%	$5.8M-59.5%	$5.5M-64.6%	$9.0M-41.8%	$8.8M-49.8%	$14.3M-29.2%
SG&A Expenses	$3.9M+16.2%	$5.9M+1.0%	$3.7M-21.7%	$3.0M-32.9%	$3.3M-55.9%	$5.8M+9.8%	$4.7M-7.6%	$4.5M-22.3%
Operating Income	-$6.0M-500.8%	$168.9M+757.3%	-$5.3M+62.0%	-$8.7M+59.6%	$1.5M+106.9%	-$25.7M-32.7%	-$13.9M+32.8%	-$21.4M+0.5%
EBITDA	-$6.0M-497.1%	$168.9M+765.8%	-$5.3M+61.2%	-$8.6M+59.0%	$1.5M+107.1%	-$25.4M-33.5%	-$13.6M+33.3%	-$21.1M+0.4%
Interest Expense	$18K-35.7%	$17K-39.3%	$18K-40.0%	$23K-20.7%	$28K-17.6%	$28K-36.4%	$30K-31.8%	$29K-37.0%
Income Tax	N/A	$0	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$5.1M-303.8%	$169.7M+791.9%	-$3.8M+70.0%	-$7.7M+60.7%	$2.5M+112.7%	-$24.5M-37.2%	-$12.5M+35.1%	-$19.7M+1.9%
EPS (Basic)	-$0.03-400.0%	$0.88+776.9%	-$0.01+85.7%	-$0.04+60.0%	$0.01+109.1%	-$0.13-30.0%	-$0.07+41.7%	-$0.10+16.7%
EPS (Diluted)	-$0.03-400.0%	$0.87+769.2%	-$0.01	-$0.04+60.0%	$0.01+109.1%	-$0.13-30.0%	-$0.07+41.7%	-$0.10+16.7%
Diluted Shares (Avg)	197M+2.6%	195M+2.4%	N/A	192M+1.5%	192M+2.3%	191M+8.6%	N/A	189M+12.8%

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.

ABUS Balance Sheet

ABUS quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$94.6M-28.2%	$131.7M-8.8%	$144.4M-26.1%	$195.4M-4.4%	$204.5M+49.2%	$137.1M+29.9%	$105.5M-53.7%	$227.9M-3.9%	$237.2M-14.0%	$275.9M-61.3%	$712.3M+502.7%	$118.2M+64.8%	$71.7M	N/A	N/A
Current Assets	$94.5M-25.8%	$127.3M-3.6%	$132.0M-12.6%	$151.1M-5.9%	$160.7M+25.8%	$127.7M+36.1%	$93.8M-27.4%	$129.2M-0.1%	$129.4M-2.4%	$132.6M-27.9%	$183.9M+57.9%	$116.4M+65.5%	$70.3M	N/A	N/A
Cash & Equivalents	$18.0M-50.4%	$36.3M+38.2%	$26.3M-14.6%	$30.8M-71.8%	$109.3M+109.1%	$52.3M+64.3%	$31.8M-13.9%	$36.9M-32.0%	$54.3M+131.9%	$23.4M-86.0%	$166.8M+131.0%	$72.2M+5.0%	$68.7M+46.1%	$47.0M+420.7%	$9.0M
Short-Term Investments	$73.5M-14.9%	$86.3M-13.5%	$99.7M-14.1%	$116.1M+152.3%	$46.0M-35.2%	$71.0M+20.3%	$59.0M-32.7%	$87.7M+21.7%	$72.1M-32.7%	$107.1M+637.7%	$14.5M-63.7%	$40.0M	$0	$0	$0
Accounts Receivable	$1.4M-39.9%	$2.4M+35.6%	$1.8M+31.4%	$1.4M+50.4%	$899K-31.5%	$1.3M+9.0%	$1.2M-15.9%	$1.4M+256.0%	$402K+47.3%	$273K-72.9%	$1.0M-47.0%	$1.9M+1526.5%	$117K-89.1%	$1.1M	N/A
Long-Term Investments	$0	$0-100.0%	$6.3M-83.2%	$37.4M+4.7%	$35.7M	$0	$0	$0	$0	$0-100.0%	$10.1M	$0	$0	$0	$0
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	$0-100.0%	$22.5M-7.8%	$24.4M0.0%	$24.4M-85.0%	$162.5M	$0	N/A	N/A	N/A
Total Liabilities	$18.0M-47.5%	$34.3M-10.5%	$38.4M-34.5%	$58.6M+67.1%	$35.0M-0.2%	$35.1M+7.1%	$32.8M+18.5%	$27.7M-49.4%	$54.7M-25.0%	$72.9M-55.7%	$164.6M+446.1%	$30.1M+140.7%	$12.5M	N/A	N/A
Current Liabilities	$6.0M-61.5%	$15.6M-30.5%	$22.5M-31.6%	$32.9M+192.8%	$11.2M+17.6%	$9.5M+21.9%	$7.8M-30.3%	$11.2M-23.2%	$14.6M+38.2%	$10.6M+0.1%	$10.6M-47.6%	$20.2M+61.4%	$12.5M	N/A	N/A
Non-Current Liabilities	$12.0M-35.7%	$18.7M+17.8%	$15.9M-38.2%	$25.7M+7.9%	$23.8M-6.8%	$25.6M+2.4%	$25.0M+51.9%	$16.4M-59.0%	$40.1M-35.7%	$62.3M-59.5%	$154.0M+1450.1%	$9.9M	$0	N/A	N/A
Long-Term Debt	$0	$0	$0	$0	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$76.6M-21.4%	$97.4M-8.2%	$106.0M-22.5%	$136.9M-19.2%	$169.4M+66.2%	$102.0M+40.2%	$72.7M-63.7%	$200.2M+9.7%	$182.5M-10.1%	$203.0M-62.9%	$547.7M+522.1%	$88.0M+48.7%	$59.2M+44.7%	$40.9M+682.7%	$5.2M
Retained Earnings	-$1.4B-2.5%	-$1.3B-5.5%	-$1.3B-6.1%	-$1.2B-6.1%	-$1.1B-8.5%	-$1.0B-7.8%	-$970.1M-20.5%	-$805.2M-9.1%	-$738.1M-13.1%	-$652.7M-144.5%	-$267.0M-29.7%	-$205.9M-23.3%	-$167.0M	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$274.0M+165.4%	$277.2M+136.9%	$94.6M-28.2%	$97.7M-30.4%	$103.3M-35.5%	$117.0M-22.1%	$131.7M-8.8%	$140.4M-11.5%
Current Assets	$273.9M+165.6%	$277.0M+137.2%	$94.5M-25.8%	$97.4M-26.6%	$103.1M-30.4%	$116.8M-14.0%	$127.3M-3.6%	$132.8M-6.2%
Cash & Equivalents	$19.2M-48.8%	$23.7M-36.1%	$18.0M-50.4%	$22.4M-29.6%	$37.4M-40.4%	$37.1M-14.0%	$36.3M+38.2%	$31.8M+81.7%
Short-Term Investments	$73.5M+21.1%	$71.5M-5.4%	$73.5M-14.9%	$71.3M-25.7%	$60.7M-23.4%	$75.6M-12.2%	$86.3M-13.5%	$95.9M-17.7%
Accounts Receivable	$369K-64.0%	$1.3M+11.0%	$1.4M-39.9%	$905K-43.7%	$1.0M-42.0%	$1.2M-44.7%	$2.4M+35.6%	$1.6M-25.9%
Long-Term Investments	$0	$0	$0	$0-100.0%	$0-100.0%	$0-100.0%	$0-100.0%	$3.0M-71.8%
Total Liabilities	$15.3M-24.6%	$17.0M-55.1%	$18.0M-47.5%	$20.3M-39.5%	$20.3M-46.0%	$37.9M+6.2%	$34.3M-10.5%	$33.6M-14.6%
Current Liabilities	$3.4M-33.0%	$5.1M-73.7%	$6.0M-61.5%	$5.2M-72.6%	$5.0M-77.8%	$19.4M-4.3%	$15.6M-30.5%	$18.9M-15.2%
Non-Current Liabilities	$11.9M-21.9%	$11.9M-35.5%	$12.0M-35.7%	$15.1M+3.4%	$15.3M+1.8%	$18.4M+20.0%	$18.7M+17.8%	$14.6M-13.9%
Long-Term Debt	$0	$0	$0	$0	$0	$0	$0	$0
Total Equity	$258.7M+211.8%	$260.2M+228.7%	$76.6M-21.4%	$77.4M-27.6%	$83.0M-32.2%	$79.2M-30.9%	$97.4M-8.2%	$106.9M-10.4%
Retained Earnings	-$1.2B+11.2%	-$1.2B+11.7%	-$1.4B-2.5%	-$1.4B-3.2%	-$1.4B-4.1%	-$1.4B-5.9%	-$1.3B-5.5%	-$1.3B-6.1%

Not reported in any period shown, so not listed: Inventory, Goodwill.

ABUS Cash Flow Statement

ABUS quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	-$24.6M	-$39.6M+38.9%	-$64.8M+24.5%	-$85.9M-143.1%	-$35.4M+47.6%	-$67.5M-31.3%	-$51.4M+27.6%	-$71.0M-4.6%	-$67.9M-39.5%	-$48.6M+16.0%	-$57.9M-2.7%	-$56.4M-353.9%	-$12.4M-84.4%	-$6.7M-120.5%	$32.9M+520.2%	-$7.8M
Depreciation & Amortization	N/A	$363K-73.7%	$1.4M-1.7%	$1.4M-1.6%	$1.4M-18.6%	$1.8M-11.4%	$2.0M-2.5%	$2.0M-7.0%	$2.2M+7.6%	$2.0M+85.6%	$1.1M+85.4%	$589K+11.3%	$529K-13.7%	$613K-29.2%	$866K-12.3%	$987K
Stock-Based Compensation	N/A	$7.0M-22.6%	$9.0M-3.4%	$9.3M+29.5%	$7.2M+11.8%	$6.4M+4.3%	$6.2M-9.4%	$6.8M+8.9%	$6.2M-58.7%	$15.1M-61.4%	$39.2M+77.2%	$22.1M+573.0%	$3.3M+263.6%	$903K-8.1%	$982K+55.1%	$633K
Capital Expenditures	N/A	$0-100.0%	$182K-81.9%	$1.0M+96.9%	$512K-36.7%	$809K+253.3%	$229K-61.1%	$589K-48.2%	$1.1M-84.3%	$7.3M+81.8%	$4.0M+74.7%	$2.3M+116.6%	$1.1M+45.7%	$725K+4733.3%	$15K-75.2%	$60K
Free Cash Flow	N/A	-$39.6M+39.1%	-$65.0M+25.2%	-$86.9M-142.4%	-$35.9M+47.5%	-$68.3M-32.3%	-$51.7M+27.8%	-$71.6M-3.8%	-$69.0M-23.4%	-$55.9M+9.7%	-$61.9M-5.5%	-$58.7M-335.3%	-$13.5M-80.6%	-$7.5M-122.7%	$32.9M+516.8%	-$7.9M
Investing Cash Flow	-$10.8M	$15.6M-32.1%	$22.9M-54.8%	$50.8M+167.7%	-$74.9M-491.1%	-$12.7M+15.0%	-$14.9M-152.6%	$28.3M+786.6%	-$4.1M-114.8%	$27.8M+128.1%	-$99.1M-1390.3%	$7.7M+117.9%	-$43.0M-5825.2%	-$725K-5941.7%	-$12K+80.1%	-$60K
Financing Cash Flow	$17.3M	$5.7M-89.0%	$52.0M+69.7%	$30.6M-3.7%	$31.8M-76.8%	$137.2M+58.2%	$86.7M+131.6%	$37.5M-32.7%	$55.6M+12.8%	$49.3M+290.3%	$12.6M-91.2%	$143.9M+137.1%	$60.7M+85.5%	$32.7M+619.5%	$4.5M-1.4%	$4.6M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$6.0M+61.8%	-$8.1M+39.4%	-$4.7M+54.6%	-$5.8M+71.9%	-$15.7M-8.6%	-$13.4M+30.6%	-$10.3M+40.3%	-$20.7M+4.8%
Depreciation & Amortization	$11K0.0%	$11K-96.7%	$11K-96.7%	$11K-96.7%	$11K-96.9%	$330K-7.0%	$333K-7.2%	$336K-8.9%
Stock-Based Compensation	$1.6M+108.8%	$1.4M-61.9%	N/A	$1.2M-44.4%	$764K-76.0%	$3.6M+77.0%	N/A	$2.2M-13.0%
Capital Expenditures	N/A	N/A	$0-100.0%	$0	$0-100.0%	$0-100.0%	$86K	$0-100.0%
Free Cash Flow	N/A	N/A	-$4.7M+55.0%	-$5.8M+71.9%	-$15.7M-8.6%	-$13.4M+30.9%	-$10.4M+39.9%	-$20.7M+5.0%
Investing Cash Flow	-$1.7M-110.6%	$2.2M-80.6%	-$1.4M-110.1%	-$10.0M+16.4%	$15.6M+58.8%	$11.3M-3.0%	$13.4M-39.7%	-$12.0M-214.9%
Financing Cash Flow	$3.1M+594.9%	$11.6M+317.3%	$1.6M+15.4%	$844K-52.5%	$453K-98.1%	$2.8M-88.6%	$1.4M-62.7%	$1.8M+5.6%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

ABUS Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ABUS quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Margin	-271.0%	-1236.7%	-430.5%	-167.8%	-669.1%	-836.1%	-2394.0%	-1510.2%	-1036.7%	-32973.8%	-446.5%	-223.6%	-78.6%+13.2pp	-91.8%-28.2pp	-63.6%
Net Margin	-237.9%	-1133.0%	-401.6%	-178.0%	-693.9%	-922.0%	-2557.4%	-959.8%	-788.9%	-25765.5%	-269.4%	-259.7%	-90.9%	209.9%	-60.0%
Return on Equity	-43.8%+28.1pp	-71.8%-3.1pp	-68.7%-18.0pp	-50.7%-5.7pp	-45.0%+17.5pp	-62.5%+148.8pp	-211.3%-182.8pp	-28.5%+17.8pp	-46.3%+143.0pp	-189.2%-177.8pp	-11.5%+32.7pp	-44.1%-20.4pp	-23.8%-96.1pp	72.4%+265.2pp	-192.9%
Return on Assets	-35.4%+17.7pp	-53.1%-2.6pp	-50.4%-14.9pp	-35.5%+1.8pp	-37.3%+9.2pp	-46.5%+99.2pp	-145.7%-120.6pp	-25.0%+10.5pp	-35.6%+103.6pp	-139.2%-130.4pp	-8.8%+24.1pp	-32.9%-13.3pp	-19.6%	N/A	N/A
Current Ratio	15.73+7.6x	8.15+2.3x	5.87+1.3x	4.60-9.7x	14.32+0.9x	13.38+1.4x	11.99+0.5x	11.50+2.7x	8.84-3.7x	12.52-4.9x	17.38+11.6x	5.76+0.1x	5.62	N/A	N/A
Debt-to-Equity	0.000.0x	0.000.0x	0.000.0x	0.000.0x	0.00-0.3x	0.34-0.1x	0.45+0.3x	0.14-0.2x	0.30-0.1x	0.36+0.1x	0.300.0x	0.34+0.1x	0.21	N/A	N/A
Asset Turnover	0.15+0.1x	0.05-0.1x	0.13-0.1x	0.20+0.1x	0.050.0x	0.050.0x	0.060.0x	0.030.0x	0.050.0x	0.010.0x	0.03-0.1x	0.13-0.1x	0.22	N/A	N/A
FCF Margin	-281.4%	-1053.8%	-479.3%	-91.9%	-622.0%	-747.3%	-1191.1%	-1160.7%	-522.5%	-4150.3%	-252.1%	-90.1%-41.9pp	-48.3%	233.2%	-46.9%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Margin	-588.2%	94.3%	-503.3%	-1636.9%	13.9%	-1456.9%	-885.2%	-1601.2%
Net Margin	-507.2%	94.7%	-357.4%	-1463.5%	23.5%	-1390.4%	-796.2%	-1472.5%
Return on Equity	-2.0%-5.0pp	65.2%+96.2pp	-4.9%+8.0pp	-10.0%+8.4pp	3.0%+19.2pp	-31.0%-15.4pp	-12.9%+5.3pp	-18.4%-1.6pp
Return on Assets	-1.9%-4.3pp	61.2%+82.2pp	-4.0%+5.6pp	-7.9%+6.1pp	2.4%+14.8pp	-21.0%-9.1pp	-9.5%+3.9pp	-14.0%-1.4pp
Current Ratio	81.42+60.9x	54.26+48.3x	15.73+7.6x	18.80+11.8x	20.53+14.0x	6.01-0.7x	8.15+2.3x	7.02+0.7x
Debt-to-Equity	0.000.0x	0.000.0x	0.000.0x	0.000.0x	0.000.0x	0.000.0x	0.000.0x	0.000.0x
Asset Turnover	0.00-0.1x	0.65+0.6x	0.010.0x	0.010.0x	0.10+0.1x	0.020.0x	0.010.0x	0.010.0x
FCF Margin	N/A	N/A	-445.3%	-1099.6%	-146.6%	-759.1%	-660.8%	-1548.6%

Not reported in any period shown, so not listed: Gross Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Arbutus Biopharma Corporation ABUS	FY2025	$14.1M	-$33.5M	N/A	$836.0M	63/100
Spyre Therapeutics, Inc. SYRE	FY2025	$0	-$155.2M	N/A	$7.5B	—
uniQure N.V. QURE	FY2025	$16.1M	-$199.0M	N/A	$1.6B	44/100
CorMedix Inc. CRMD	FY2025	$311.7M	$163.1M	52.3%	$581.5M	50/100
EyePoint, Inc. EYPT	FY2025	$31.4M	-$232.0M	N/A	$270.7M	46/100

Where Arbutus Biopharma Corporation Ranks

Frequently Asked Questions

What is Arbutus Biopharma Corporation's annual revenue?

Arbutus Biopharma Corporation (ABUS) reported $14.1M in total revenue for fiscal year 2025. This represents a 128.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Arbutus Biopharma Corporation's revenue growing?

Arbutus Biopharma Corporation (ABUS) revenue grew by 128.2% year-over-year, from $6.2M to $14.1M in fiscal year 2025.

Is Arbutus Biopharma Corporation profitable?

No, Arbutus Biopharma Corporation (ABUS) reported a net income of -$33.5M in fiscal year 2025.

What is Arbutus Biopharma Corporation's EBITDA?

Arbutus Biopharma Corporation (ABUS) had EBITDA of -$37.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Arbutus Biopharma Corporation have?

As of fiscal year 2025, Arbutus Biopharma Corporation (ABUS) had $18.0M in cash and equivalents against $0 in long-term debt.

What is Arbutus Biopharma Corporation's return on equity (ROE)?

Arbutus Biopharma Corporation (ABUS) has a return on equity of -43.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Arbutus Biopharma Corporation's free cash flow?

Arbutus Biopharma Corporation (ABUS) recorded an outflow of $39.6M in free cash flow during fiscal year 2025. This represents a 39.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Arbutus Biopharma Corporation's operating cash flow?

Arbutus Biopharma Corporation (ABUS) recorded an outflow of $39.6M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Arbutus Biopharma Corporation's total assets?

Arbutus Biopharma Corporation (ABUS) had $94.6M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Arbutus Biopharma Corporation's capital expenditures?

Arbutus Biopharma Corporation (ABUS) reported no capital expenditure during fiscal year 2025.

How much does Arbutus Biopharma Corporation spend on research and development?

Arbutus Biopharma Corporation (ABUS) invested $25.2M in research and development during fiscal year 2025.

How many shares does Arbutus Biopharma Corporation have outstanding?

Arbutus Biopharma Corporation (ABUS) had 195M shares outstanding as of fiscal year 2025.

What is Arbutus Biopharma Corporation's current ratio?

Arbutus Biopharma Corporation (ABUS) had a current ratio of 15.73 as of fiscal year 2025, which is generally considered healthy.

What is Arbutus Biopharma Corporation's debt-to-equity ratio?

Arbutus Biopharma Corporation (ABUS) had a debt-to-equity ratio of 0.00 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Arbutus Biopharma Corporation's return on assets (ROA)?

Arbutus Biopharma Corporation (ABUS) had a return on assets of -35.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Arbutus Biopharma Corporation's P/E ratio?

Arbutus Biopharma Corporation (ABUS) trades at 5.5x earnings, its market capitalization divided by net income of $153.1M net income, trailing 12 months to June 30, 2026. The market capitalization is $836.0M as of Oct 17, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Arbutus Biopharma Corporation's price-to-sales ratio?

Arbutus Biopharma Corporation (ABUS) trades at 4.6x sales, its market capitalization divided by revenue of $181.7M revenue, trailing 12 months to June 30, 2026. The market capitalization is $836.0M as of Oct 17, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Arbutus Biopharma Corporation's liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Arbutus Biopharma Corporation (ABUS) held $91.5M in cash, cash equivalents and investments, and reported an operating cash outflow of $39.6M over that year. Dividing the one by the other, the reported balance equals about 28 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Arbutus Biopharma Corporation's Altman Z-Score?

Arbutus Biopharma Corporation (ABUS) has an Altman Z-Score of 7.32, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Arbutus Biopharma Corporation's Piotroski F-Score?

Arbutus Biopharma Corporation (ABUS) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Arbutus Biopharma Corporation's earnings high quality?

Arbutus Biopharma Corporation (ABUS) reported a net loss of $33.5M while operations used $39.6M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Arbutus Biopharma Corporation cover its interest payments?

Arbutus Biopharma Corporation (ABUS) reported an operating loss of $38.2M against $97K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Arbutus Biopharma Corporation?

Arbutus Biopharma Corporation (ABUS) scores 63 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.